Gilead Sciences (GILD) 101.04 $GILD Midday Glan
Post# of 64070
Posted On: 03/16/2015 1:51:13 PM
Gilead Sciences (GILD) 101.04 $GILD
Midday Glance: Biotechnology companies
AP - 31 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
GILD: 101.04 (+1.43), AMGN: 161.88 (+7.62), CELG: 120.25 (+2.52)
Early Glance: Biotechnology companies
AP - Mon Mar 16, 9:34AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
GILD: 101.04 (+1.43), AMGN: 161.88 (+7.62), CELG: 120.25 (+2.52)
3 Biotech Stocks Wall Street Loves
Keith Speights, The Motley Fool - Motley Fool - Mon Mar 16, 7:01AM CDT
Source: Wikimedia Commons . How can you know when Wall Street really loves a stock? One key sign is how many of the analysts covering the stock maintain buy ratings. Another tell-tale indicator is the price targets these analysts give for the...
GILD: 101.04 (+1.43), ALXN: 178.45 (+1.56), CELG: 120.25 (+2.52)
Is This Number the Scariest Healthcare Statistic Out There?
Todd Campbell, The Motley Fool - Motley Fool - Sun Mar 15, 12:01PM CDT
Source: Flickr user Chris Potter Healthcare has no shortage of frightening statistics, but a recent review of U.S. spending on medicine last year by the pharmacy benefit manager Express Scripts contained a particularly scary revelation: Last...
ESRX: 83.54 (+2.17), GILD: 101.04 (+1.43), CVS: 104.19 (+0.93), ABBV: 58.87 (+0.87)
Should Gilead Sciences Inc.’s Slowing Growth Concern Investors?
George Budwell, The Motley Fool - Motley Fool - Sun Mar 15, 7:57AM CDT
The failure of the market to buy into Gilead Sciences ' amazing growth story is a flat-out mystery in the eyes of many investors. Despite growing product sales by an astounding 127% and non-GAAP earnings per share by 297% last year, the stock has...
BIIB: 420.75 (+7.40), ESRX: 83.54 (+2.17), GILD: 101.04 (+1.43), AMGN: 161.88 (+7.62), ABBV: 58.87 (+0.87), CELG: 120.25 (+2.52)
20 Years of Improving Cancer Care Together - An NCCN Roundtable Discussion
Marketwired - Fri Mar 13, 6:00PM CDT
On March 12, 2015, as part of its 20th Annual Conference: Advancing the Standard of Cancer Care(TM), the National Comprehensive Cancer Network® (NCCN®) featured the commemorative event, 20 Years of Improving Cancer Care Together - An NCCN Roundtable Discussion. In recognition of NCCN's 20th Anniversary, this special roundtable, moderated by Clifford Goodman, PhD, The Lewin Group, featured NCCN leadership -- past and present -- as well as other stakeholders who have had a significant impact on the development, progression, and success of NCCN over the years.
GILD: 101.04 (+1.43)
Bristol-Myers Seeks Daclatasvir Approval in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 13, 3:45PM CDT
Bristol-Myers Squibb Company (BMY) announced that it has resubmitted the new drug application for hepatitis C virus candidate, daclatasvir.
CYTK: 7.75 (-0.23), GILD: 101.04 (+1.43), ABBV: 58.87 (+0.87), BMY: 67.83 (+0.96)
Seeking Alpha's Biotech Weekly: Deeper Looks At Orexigen, Pharmacyclics, And Acadia
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 13, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
ACT: 303.85 (+4.90), PCYC: 256.11 (+1.13), ITEK: 5.74 (+0.05), REDX: (), PTX: 10.11 (+0.04), CLDX: 30.78 (+1.04), ILMN: 194.83 (+6.62), IDGX: (), ACAD: 34.39 (-0.06), TRGT: 2.62 (-0.02), EXAC: 24.07 (+0.48), ABBV: 58.87 (+0.87), CRMD: 7.98 (-0.42), AGMX: (), ZGNX: 1.31 (+0.01), VVUS: 2.95 (+0.13), SPPI: 6.16 (-0.08), GSK: 46.92 (+0.55), OREX: 6.94 (-0.10), SQNM: 3.93 (+0.10), IRWD: 15.70 (+0.63), GILD: 101.04 (+1.43), MRK: 57.07 (+0.87), OHRP: 9.48 (-0.23), TEVA: 60.58 (+0.58)
Mantle Cell Lymphoma Therapeutics Pipeline Review 2015 - Featuring 39 Companies
M2 - Fri Mar 13, 10:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n2r2lq/mantle_cell) has announced the addition of the "Mantle Cell Lymphoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Mantle Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mantle Cell Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Amgen Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - Bayer AG - Bristol-Myers Squibb Company - Celgene Corporation - Celldex Therapeutics, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - EpiZyme, Inc. - Gilead Sciences, Inc. - GlaxoSmithKline plc - ImmunoGen, Inc. - Incyte Corporation - Infinity Pharmaceuticals, Inc. - Johnson & Johnson - Karyopharm Therapeutics, Inc. - Kite Pharma, Inc. - MedImmune, LLC - Merck & Co., Inc. - Novartis AG - Onyx Pharmaceuticals, Inc. - Pfizer Inc. - Pharmacyclics, Inc. - Portola Pharmaceuticals, Inc. - Seattle Genetics, Inc. - Sevion Therapeutics, Inc. - Stemline Therapeutics, Inc. - Teva Pharmaceutical Industries Limited For more information visit http://www.researchandmarkets.com/research/n2...antle_cell
PCYC: 256.11 (+1.13), CLDX: 30.78 (+1.04), EPZM: 22.20 (-0.82), STML: 16.18 (+0.17), JNJ: 100.63 (+1.42), ABBV: 58.87 (+0.87), INFI: 16.09 (+0.63), PTLA: 41.41 (+0.71), INCY: 90.72 (+1.41), PFE: 34.43 (+0.43), IMGN: 7.66 (-0.19), AMGN: 161.88 (+7.62), LLY: 71.05 (+1.16), BMY: 67.83 (+0.96), GSK: 46.92 (+0.55), SGEN: 39.06 (+0.75), GILD: 101.04 (+1.43), KITE: 63.14 (+0.05), MRK: 57.07 (+0.87), TEVA: 60.58 (+0.58), CELGZ: 3.02 (-0.03), KPTI: 30.74 (+2.66), NVS: 97.93 (+0.89)
Realistic Long-Term Growth Portfolio
The Value Portfolio - at Seeking Alpha - Fri Mar 13, 1:24AM CDT
MATW: 49.57 (+0.50), MON: 117.57 (+0.70), GILD: 101.04 (+1.43), ESV: 20.37 (-0.09), SDRL: 9.03 (-0.09), KORS: 64.45 (-0.29)
Final Glance: Biotechnology companies
AP - Thu Mar 12, 5:04PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
GILD: 101.04 (+1.43), AMGN: 161.88 (+7.62), CELG: 120.25 (+2.52)
FDA agrees to review Bristol-Myers' NDA for HCV drug
Seeking Alpha - at Seeking Alpha - Thu Mar 12, 2:49PM CDT
GILD: 101.04 (+1.43), ACHN: 11.21 (-0.09), MRK: 57.07 (+0.87), RGLS: 18.67 (-0.43), ABBV: 58.87 (+0.87), BMY: 67.83 (+0.96)
Arrowhead Trades At Just 50% Value Of ARC-520
Kanak Kanti De - at Seeking Alpha - Thu Mar 12, 12:51PM CDT
ARWR: 7.37 (-0.16), GILD: 101.04 (+1.43)
SEC to Gilead and Vertex: Let Shareholders Vote on Drug Pricing Risk Proposals
PR Newswire - Thu Mar 12, 12:00PM CDT
The U.S. Securities and Exchange Commission (SEC) denied efforts by specialty drug manufacturers Gilead Sciences and Vertex Pharmaceuticals to block shareholders from voting on proposals asking for greater transparency around the management and mitigation of the business risks from rapidly increasing U.S. drug prices. As a result of the SEC's decision, the shareholder resolutions, filed by the UAW Retiree Medical Benefits Trust (the Trust), will appear on the companies' 2015 annual meeting ballots later this year.
GILD: 101.04 (+1.43)
Gilead Sciences (GILD) Breaks Through Resistance at $99.91
Comtex SmarTrend(R) - Thu Mar 12, 11:49AM CDT
Shares of Gilead Sciences (NASDAQ:GILD) opened today above their pivot of $99.33 and have already reached the first level of resistance at $99.91. Should the shares continue to rise, the resistance pivots of $100.71 and $102.09 will be of interest.
GILD: 101.04 (+1.43)
Indian drug firm cleared to sell generic sofosbuvir
Seeking Alpha - at Seeking Alpha - Thu Mar 12, 11:44AM CDT
GILD: 101.04 (+1.43)
Midday Glance: Biotechnology companies
AP - 31 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
GILD: 101.04 (+1.43), AMGN: 161.88 (+7.62), CELG: 120.25 (+2.52)
Early Glance: Biotechnology companies
AP - Mon Mar 16, 9:34AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
GILD: 101.04 (+1.43), AMGN: 161.88 (+7.62), CELG: 120.25 (+2.52)
3 Biotech Stocks Wall Street Loves
Keith Speights, The Motley Fool - Motley Fool - Mon Mar 16, 7:01AM CDT
Source: Wikimedia Commons . How can you know when Wall Street really loves a stock? One key sign is how many of the analysts covering the stock maintain buy ratings. Another tell-tale indicator is the price targets these analysts give for the...
GILD: 101.04 (+1.43), ALXN: 178.45 (+1.56), CELG: 120.25 (+2.52)
Is This Number the Scariest Healthcare Statistic Out There?
Todd Campbell, The Motley Fool - Motley Fool - Sun Mar 15, 12:01PM CDT
Source: Flickr user Chris Potter Healthcare has no shortage of frightening statistics, but a recent review of U.S. spending on medicine last year by the pharmacy benefit manager Express Scripts contained a particularly scary revelation: Last...
ESRX: 83.54 (+2.17), GILD: 101.04 (+1.43), CVS: 104.19 (+0.93), ABBV: 58.87 (+0.87)
Should Gilead Sciences Inc.’s Slowing Growth Concern Investors?
George Budwell, The Motley Fool - Motley Fool - Sun Mar 15, 7:57AM CDT
The failure of the market to buy into Gilead Sciences ' amazing growth story is a flat-out mystery in the eyes of many investors. Despite growing product sales by an astounding 127% and non-GAAP earnings per share by 297% last year, the stock has...
BIIB: 420.75 (+7.40), ESRX: 83.54 (+2.17), GILD: 101.04 (+1.43), AMGN: 161.88 (+7.62), ABBV: 58.87 (+0.87), CELG: 120.25 (+2.52)
20 Years of Improving Cancer Care Together - An NCCN Roundtable Discussion
Marketwired - Fri Mar 13, 6:00PM CDT
On March 12, 2015, as part of its 20th Annual Conference: Advancing the Standard of Cancer Care(TM), the National Comprehensive Cancer Network® (NCCN®) featured the commemorative event, 20 Years of Improving Cancer Care Together - An NCCN Roundtable Discussion. In recognition of NCCN's 20th Anniversary, this special roundtable, moderated by Clifford Goodman, PhD, The Lewin Group, featured NCCN leadership -- past and present -- as well as other stakeholders who have had a significant impact on the development, progression, and success of NCCN over the years.
GILD: 101.04 (+1.43)
Bristol-Myers Seeks Daclatasvir Approval in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 13, 3:45PM CDT
Bristol-Myers Squibb Company (BMY) announced that it has resubmitted the new drug application for hepatitis C virus candidate, daclatasvir.
CYTK: 7.75 (-0.23), GILD: 101.04 (+1.43), ABBV: 58.87 (+0.87), BMY: 67.83 (+0.96)
Seeking Alpha's Biotech Weekly: Deeper Looks At Orexigen, Pharmacyclics, And Acadia
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 13, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
ACT: 303.85 (+4.90), PCYC: 256.11 (+1.13), ITEK: 5.74 (+0.05), REDX: (), PTX: 10.11 (+0.04), CLDX: 30.78 (+1.04), ILMN: 194.83 (+6.62), IDGX: (), ACAD: 34.39 (-0.06), TRGT: 2.62 (-0.02), EXAC: 24.07 (+0.48), ABBV: 58.87 (+0.87), CRMD: 7.98 (-0.42), AGMX: (), ZGNX: 1.31 (+0.01), VVUS: 2.95 (+0.13), SPPI: 6.16 (-0.08), GSK: 46.92 (+0.55), OREX: 6.94 (-0.10), SQNM: 3.93 (+0.10), IRWD: 15.70 (+0.63), GILD: 101.04 (+1.43), MRK: 57.07 (+0.87), OHRP: 9.48 (-0.23), TEVA: 60.58 (+0.58)
Mantle Cell Lymphoma Therapeutics Pipeline Review 2015 - Featuring 39 Companies
M2 - Fri Mar 13, 10:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n2r2lq/mantle_cell) has announced the addition of the "Mantle Cell Lymphoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Mantle Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mantle Cell Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Amgen Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - Bayer AG - Bristol-Myers Squibb Company - Celgene Corporation - Celldex Therapeutics, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - EpiZyme, Inc. - Gilead Sciences, Inc. - GlaxoSmithKline plc - ImmunoGen, Inc. - Incyte Corporation - Infinity Pharmaceuticals, Inc. - Johnson & Johnson - Karyopharm Therapeutics, Inc. - Kite Pharma, Inc. - MedImmune, LLC - Merck & Co., Inc. - Novartis AG - Onyx Pharmaceuticals, Inc. - Pfizer Inc. - Pharmacyclics, Inc. - Portola Pharmaceuticals, Inc. - Seattle Genetics, Inc. - Sevion Therapeutics, Inc. - Stemline Therapeutics, Inc. - Teva Pharmaceutical Industries Limited For more information visit http://www.researchandmarkets.com/research/n2...antle_cell
PCYC: 256.11 (+1.13), CLDX: 30.78 (+1.04), EPZM: 22.20 (-0.82), STML: 16.18 (+0.17), JNJ: 100.63 (+1.42), ABBV: 58.87 (+0.87), INFI: 16.09 (+0.63), PTLA: 41.41 (+0.71), INCY: 90.72 (+1.41), PFE: 34.43 (+0.43), IMGN: 7.66 (-0.19), AMGN: 161.88 (+7.62), LLY: 71.05 (+1.16), BMY: 67.83 (+0.96), GSK: 46.92 (+0.55), SGEN: 39.06 (+0.75), GILD: 101.04 (+1.43), KITE: 63.14 (+0.05), MRK: 57.07 (+0.87), TEVA: 60.58 (+0.58), CELGZ: 3.02 (-0.03), KPTI: 30.74 (+2.66), NVS: 97.93 (+0.89)
Realistic Long-Term Growth Portfolio
The Value Portfolio - at Seeking Alpha - Fri Mar 13, 1:24AM CDT
MATW: 49.57 (+0.50), MON: 117.57 (+0.70), GILD: 101.04 (+1.43), ESV: 20.37 (-0.09), SDRL: 9.03 (-0.09), KORS: 64.45 (-0.29)
Final Glance: Biotechnology companies
AP - Thu Mar 12, 5:04PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
GILD: 101.04 (+1.43), AMGN: 161.88 (+7.62), CELG: 120.25 (+2.52)
FDA agrees to review Bristol-Myers' NDA for HCV drug
Seeking Alpha - at Seeking Alpha - Thu Mar 12, 2:49PM CDT
GILD: 101.04 (+1.43), ACHN: 11.21 (-0.09), MRK: 57.07 (+0.87), RGLS: 18.67 (-0.43), ABBV: 58.87 (+0.87), BMY: 67.83 (+0.96)
Arrowhead Trades At Just 50% Value Of ARC-520
Kanak Kanti De - at Seeking Alpha - Thu Mar 12, 12:51PM CDT
ARWR: 7.37 (-0.16), GILD: 101.04 (+1.43)
SEC to Gilead and Vertex: Let Shareholders Vote on Drug Pricing Risk Proposals
PR Newswire - Thu Mar 12, 12:00PM CDT
The U.S. Securities and Exchange Commission (SEC) denied efforts by specialty drug manufacturers Gilead Sciences and Vertex Pharmaceuticals to block shareholders from voting on proposals asking for greater transparency around the management and mitigation of the business risks from rapidly increasing U.S. drug prices. As a result of the SEC's decision, the shareholder resolutions, filed by the UAW Retiree Medical Benefits Trust (the Trust), will appear on the companies' 2015 annual meeting ballots later this year.
GILD: 101.04 (+1.43)
Gilead Sciences (GILD) Breaks Through Resistance at $99.91
Comtex SmarTrend(R) - Thu Mar 12, 11:49AM CDT
Shares of Gilead Sciences (NASDAQ:GILD) opened today above their pivot of $99.33 and have already reached the first level of resistance at $99.91. Should the shares continue to rise, the resistance pivots of $100.71 and $102.09 will be of interest.
GILD: 101.04 (+1.43)
Indian drug firm cleared to sell generic sofosbuvir
Seeking Alpha - at Seeking Alpha - Thu Mar 12, 11:44AM CDT
GILD: 101.04 (+1.43)
(0)
(0)Scroll down for more posts ▼